2022
Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
Brasky T, Hade E, Cohn D, Newton A, Petruzella S, O'Connell K, Bertrand K, Cook L, De Vivo I, Du M, Freudenheim J, Friedenreich C, Goodman M, Gorzelitz J, Ibiebele T, Krogh V, Liao L, Lipworth L, Lu L, McCann S, O'Mara T, Palmer J, Ponte J, Prizment A, Risch H, Sandin S, Schouten L, Setiawan V, Shu X, Trabert B, van den Brandt P, Webb P, Wentzensen N, Wilkens L, Wolk A, Yu H, Neuhouser M. Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis. Gynecologic Oncology 2022, 169: 137-146. PMID: 36934308, PMCID: PMC10025515, DOI: 10.1016/j.ygyno.2022.10.015.Peer-Reviewed Original ResearchMeSH KeywordsDietEndometrial NeoplasmsFatty Acids, Omega-3FemaleHumansLogistic ModelsObesityOverweightProspective StudiesRisk FactorsConceptsEndometrial cancer riskEndometrial Cancer ConsortiumHigh dietary intakeCancer riskDietary intakeObese womenOdds ratioCancer ConsortiumDietary omega-3 fatty acidsOmega-3 fatty acidsEnergy-adjusted quartilesEndometrial cancer casesEndometrial cancer incidenceProspective cohort studyFood frequency questionnaireNormal-weight womenFatty acid intakeAdjusted odds ratioBody mass indexLong-chain omega-3Anti-inflammatory propertiesSubgroup of womenConfidence intervalsCase-control studyTwo-stage individual participant data
2009
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox Jr J, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009, 41: 986-990. PMID: 19648918, PMCID: PMC2839871, DOI: 10.1038/ng.429.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAllelesCase-Control StudiesChromosomes, Human, Pair 9Cohort StudiesFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic VariationGenome-Wide Association StudyGenotypeHaplotypesHumansIntronsLinkage DisequilibriumLogistic ModelsMaleOdds RatioPancreatic NeoplasmsPolymorphism, Single NucleotideProspective StudiesRisk FactorsUnited States
2008
Associations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in Women
Strickler H, Fazzari M, Kovacs A, Isasi C, Napolitano L, Minkoff H, Gange S, Young M, Sharp G, Kaplan R, Cohen M, Gunter M, Harris T, Yu H, Schoenbaum E, Landay A, Anastos K. Associations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in Women. The Journal Of Infectious Diseases 2008, 197: 319-327. PMID: 18177247, PMCID: PMC3127259, DOI: 10.1086/524848.Peer-Reviewed Original ResearchConceptsHIV disease progressionT-cell count declineCell count declineDisease progressionIGFBP-3Count declineIGF axisHuman immunodeficiency virus (HIV) disease progressionInsulin-like growth factor (IGF) axisHigher IGFBP-3 levelsIGF-Binding Protein-3Low IGF-I levelsInsulin-like growth factorIGFBP-3 levelsUse of HAARTBaseline serum samplesIGF-I levelsIGF-binding proteinsGrowth factor axisHIV pathogenesisLymphocyte numbersSerum levelsThymic growthImmunodeficiency syndromeMultivariable model
2004
Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care Clinics
Huang J, Yu H, Marin E, Brock S, Carden D, Davis T. Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care Clinics. Academic Medicine 2004, 79: 156-161. PMID: 14744717, DOI: 10.1097/00001888-200402000-00012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAttitude of Health PersonnelClinical CompetenceCounselingDiabetes Mellitus, Type 2FemaleFocus GroupsHospitals, PublicHumansHyperlipidemiasInterviews as TopicLogistic ModelsLouisianaMaleMiddle AgedObesityOutpatient Clinics, HospitalPhysician's RolePractice Patterns, Physicians'Primary Health CareSampling StudiesWeight LossConceptsWeight loss counselingWeight loss recommendationsPrimary care clinicsPatient understandingWeight lossCare clinicsPatient recallLouisiana State University Health Sciences Center-ShreveportHospital primary care clinicPrimary care physiciansWeight loss strategiesRisk of obesityWeight management strategiesDistinct clinical diagnosisStage of readinessStructured exit interviewsObese patientsPhysician counselingCare physiciansPhysician barriersWeight managementLoss strategiesClinical diagnosisPatientsPhysicians
2003
Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)
Li L, Yu H, Schumacher F, Casey G, Witte J. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes & Control 2003, 14: 721-726. PMID: 14674736, DOI: 10.1023/a:1026383824791.Peer-Reviewed Original ResearchConceptsIGFBP-3 molar ratioInsulin-like growth factorIGFBP-3Prostate cancerHigher IGFOdds ratioSibling-matched case-control studySerum insulin-like growth factorInsulin-like growth factor IProtein 3Growth factorIGFBP-3 associationSerum IGF levelsEffects of IGFConfidence intervalsImportant risk factorCase-control studyConditional logistic regressionGrowth factor IProstatic epithelial cellsAdvanced diseaseSerum IGFIGF levelsAggressive diseaseRisk factors
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigen